Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer
ERpHER2n HRD tumors show features of aggressive disease, but do not display a distinct transcriptional or DNA methylation profile that clearly differentiates them from HR-proficient tumors. Though numbers are limited, we present early evidence that HRD stratification by WGS could impact therapeutic strategies, as HRD BCs trended to poorer outcomes when not treated with chemotherapy.
Authors
- Daniella Black
- Frida Rosengren (ORCID: https://orcid.org/0000-0002-8724-757X)
- K. Sigurjónsdóttir
- Ziqian Chen (ORCID: https://orcid.org/0000-0003-3870-9464)
- L. Hohmann (ORCID: https://orcid.org/0000-0002-0281-7140)
- Helen R. Davies (ORCID: https://orcid.org/0000-0002-2791-0528)
- Johan Vallon‐Christersson (ORCID: https://orcid.org/0000-0002-2195-0385)
- Ana Bosch (ORCID: https://orcid.org/0000-0003-0666-5946)
- Srinivas Veerla (ORCID: https://orcid.org/0000-0001-7328-6239)
- Giuseppe Rinaldi (ORCID: https://orcid.org/0000-0002-5650-6049)
- Y. Memari
- Professor Serena Nik-Zainal
- Nicklas Nordborg
- Åke Borg
- Johan Staaf
- Deborah F. Nacer
- Anders Kvist
- Jari Häkkinen
- Ramsay Bowden
Institutions
- Lund University (SE)
- Cancer Research UK (GB)
- Medicon Village (SE)
- Cancer Research UK Cambridge Center (GB)
- Skåne University Hospital (SE)
Publication Details
- Journal
- Communications Medicine
- Published
- 2026-02-16
- DOI
- https://doi.org/10.1038/s43856-026-01385-0
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Breast Cancer Research Foundation
- Mats Paulssons Stiftelse
- Cancer Research UK
- National Institute for Health and Care Research
- Department of Health and Social Care
- Cancerfonden
- Lunds Universitet
- Vetenskapsrådet
- Science for Life Laboratory
- NIHR Cambridge Biomedical Research Centre